|
DSP Healthcare Fund An open ended equity scheme investing in healthcare and pharmaceutical sector |
|
|
Aditya Khemka had managed the scheme till September 11, 2020.
Vinit Sambre
Total work experience of 21 years.
Managing this Scheme since
November 2018.
Jay Kothari (Dedicated Fund
Manager for overseas investments)
Total work experience of 16 years.
Managing this Scheme since
November 2018.
Nov 30, 2018
S&P BSE HEALTHCARE (TRI)
| Regular Plan | |
| Growth: | ₹ 17.579 |
| Direct Plan | |
| Growth: | ₹ 18.157 |
₹ 833 Cr
₹ 767 Cr
0.25
| Regular Plan : | 2.36% |
| Direct Plan : | 0.93% |
Sectoral\Thematic
1 Yr 10 Mn
Holding period <12 months: 1%
Holding period >=12 months: Nil
Data As On September 30, 2020
| Name of Instrument | % to Net Assets |
| EQUITY & EQUITY RELATED | |
| Listed / awaiting listing on the stock exchanges | |
| Pharmaceuticals | 66.30 |
| ✔ Cipla Limited | 9.58 |
| ✔ Dr. Reddy's Laboratories Limited | 9.09 |
| ✔ IPCA Laboratories Limited | 7.85 |
| ✔ Divi's Laboratories Limited | 5.63 |
| ✔ Torrent Pharmaceuticals Limited | 4.77 |
| ✔ Procter & Gamble Health Limited | 4.39 |
| ✔ JB Chemicals & Pharmaceuticals Limited | 3.99 |
| Syngene International Limited | 3.08 |
| Aarti Drugs Limited | 3.02 |
| Alkem Laboratories Limited | 2.91 |
| Jubilant Life Sciences Limited | 2.70 |
| Indoco Remedies Limited | 2.55 |
| Alembic Pharmaceuticals Limited | 2.51 |
| Unichem Laboratories Limited | 1.93 |
| Abbott India Limited | 1.25 |
| Ajanta Pharma Limited | 1.06 |
| Healthcare Services | 14.46 |
| ✔ Apollo Hospitals Enterprise Limited | 5.43 |
| ✔ Max Healthcare Institute Ltd | 3.28 |
| Dr. Lal Path Labs Ltd. | 2.92 |
| Narayana Hrudayalaya Ltd. | 2.83 |
| Finance | 3.77 |
| ✔ ICICI Lombard General Insurance Company Limited | 3.77 |
| Total | 84.54 |
| Foreign Securities and/or overseas ETF(s) | |
| Listed / awaiting listing on the stock exchanges | |
| Pharmaceuticals | 6.17 |
| Intuitive Surgical Inc | 3.23 |
| Abbott Laboratories | 2.95 |
| Healthcare Services | 2.75 |
| Abiomed Inc | 2.75 |
| Total | 8.93 |
| MONEY MARKET INSTRUMENTS | |
| TREPS / Reverse Repo Investments / Corporate Debt Repo | 10.04 |
| Total | 10.04 |
| Cash & Cash Equivalent | |
| Net Receivables/Payables | -3.51 |
| Total | -3.51 |
| GRAND TOTAL | 100.00 |
as on 30th Sept'20
✔ Top Ten Holdings
| Growth of Rs. 1 L invested at inception: | 1.76 L |
| SIP Returns(In %) | ||||
| SI* | ||||
| 55.65 | ||||
| Outperformed Benchmark TRI (calendar year) |
S&P BSE HEALTHCARE (TRI)
9% |
| 1 yr | |
| Minimum (%) | -5.7 |
| Maximum (%) | 77.6 |
| Average (%) | 31.6 |
| % times negative returns | 2.4 |
| % of times returns are in excess of 7% | 88.0 |
Mid Cap: 101st -250th company in terms of full market capitalization
Small Cap: 251st company onwards in terms of full market capitalization.
| Positions Exited |
| Healthcare Services |
| Max India Limited |
| Positions Increased |
| Pharmaceuticals |
| Aarti Drugs Limited |
| Torrent Pharmaceuticals Limited |
| Cipla Limited |
| Alembic Pharmaceuticals Limited |
| Dr. Reddy's Laboratories Limited |
| Healthcare Services |
| Apollo Hospitals Enterprise Limited |
| Max Healthcare Institute Ltd |
| Finance |
| ICICI Lombard General Insurance Company Limited |
| Positions Decreased |
| Pharmaceuticals |
| JB Chemicals & Pharmaceuticals Limited |
Rebalances below 0.05 % are not considered.
The primary investment objective of the
scheme is to seek to generate consistent
returns by predominantly investing in
equity and equity related securities of
pharmaceutical and healthcare companies.
However, there can be no assurance that
the investment objective of the scheme will
be realized.
This open ended equity Scheme is suitable for investors who are seeking*
• Long term capital growth
• Investment in equity and equity related Securities of healthcare and pharmaceutical companies
* Investors should consult their financial advisors if in doubt whether the product is suitable for them.